Unknown

Dataset Information

0

GTPase-activating protein Rasal1 associates with ZAP-70 of the TCR and negatively regulates T-cell tumor immunity.


ABSTRACT: Immunotherapy involving checkpoint blockades of inhibitory co-receptors is effective in combating cancer. Despite this, the full range of mediators that inhibit T-cell activation and influence anti-tumor immunity is unclear. Here, we identify the GTPase-activating protein (GAP) Rasal1 as a novel TCR-ZAP-70 binding protein that negatively regulates T-cell activation and tumor immunity. Rasal1 inhibits via two pathways, the binding and inhibition of the kinase domain of ZAP-70, and GAP inhibition of the p21ras-ERK pathway. It is expressed in activated CD4 + and CD8 + T-cells, and inhibits CD4 + T-cell responses to antigenic peptides presented by dendritic cells as well as CD4 + T-cell responses to peptide antigens in vivo. Furthermore, siRNA reduction of Rasal1 expression in T-cells shrinks B16 melanoma and EL-4 lymphoma tumors, concurrent with an increase in CD8 + tumor-infiltrating T-cells expressing granzyme B and interferon γ-1. Our findings identify ZAP-70-associated Rasal1 as a new negative regulator of T-cell activation and tumor immunity.

SUBMITTER: Thaker YR 

PROVIDER: S-EPMC6805919 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4902731 | biostudies-literature
| S-EPMC3091203 | biostudies-literature
| S-EPMC3248456 | biostudies-literature
2006-09-22 | GSE4392 | GEO
2015-01-29 | E-GEOD-56017 | biostudies-arrayexpress
| S-EPMC4749924 | biostudies-literature
| S-EPMC6562615 | biostudies-literature
| S-EPMC1783460 | biostudies-literature
| S-EPMC4337460 | biostudies-literature
| S-EPMC2980477 | biostudies-literature